⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYMR News
Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
globenewswire.com
KYMR
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
globenewswire.com
KYMR
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
globenewswire.com
KYMR
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
prnewswire.com
KYMR
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
globenewswire.com
KYMR
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
globenewswire.com
KYMR
Form 8-K
sec.gov
KYMR
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com
KYMR
GILD
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
globenewswire.com
KYMR